ArticleCureus2025
Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.Journal of clinical medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the growing use of second-generation antipsychotics, it is important to consider rare but serious side effects. One such complication is diabetic ketoacidosis (DKA), representing a severe form of metabolic derangement. Moreover, neuroleptic malignant syndrome (NMS) is a rare but potentially fatal idiosyncratic reaction linked to this category of medications. We report the case of a 69-year-old male, not diabetic, who developed both DKA and NMS, with olanzapine identified as a probable culprit. He was on a steady dose of olanzapine for three months. He had significant biochemical and clinical improvement following prompt discontinuation of medication and supportive care. DKA improved within 24 hours, and NMS improved within one week. To our knowledge, this remains a very rarely reported occurrence of olanzapine-induced coexisting DKA and NMS. Early detection and treatment of such cases, particularly in patients exposed to antipsychotics, is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.